Trending

her2

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

With an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now

X

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

https://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/

FDA sets August action date for Seattle’s oral HER2 drug tucatinib

FDA sets August action date for Seattle’s oral HER2 drug tucatinib

Seattle Genetics is a few months away from having its third drug product on the market, after the

X

FDA sets August action date for Seattle’s oral HER2 drug tucatinib

https://pharmaphorum.com/news/fda-sets-august-action-date-for-seattles-oral-her2-drug-tucatinib/

Exclusive Pfizer Speaker Interview Released

Exclusive Pfizer Speaker Interview Released

Exclusive Pfizer Speaker Interview Released

X

Exclusive Pfizer Speaker Interview Released

https://pharmaphorum.com/partner-content-oncology/exclusive-pfizer-speaker-interview-released/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com